CN EN

news

BioDuro-Sundia Expands Drug Discovery Capacity and Capability

BioDuro-Sundia expands drug discovery capacity with new labs across Shanghai and Beijing, enhancing capabilities in oncology, biologics, and pharmacology.
February 13, 2023

Congratulations to NanoRay Biotech for its anticancer therapy approved by the US FDA for Clinical Trial

NanoRay Biotech’s Auger Molecular Therapy (AMT), FDA-approved for Clinical Trial, targets cancer cells via intratumoral iodine injection, using the
September 29, 2022

BioDuro-Sundia and X-Chem enter partnership to launch DEL services in China for the discovery of new small molecule drugs

Shanghai, August 8, 2022 – BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International
August 08, 2022

Bioduro-Sundia’s Wuxi GMP Manufacturing Facility Granted the Drug Manufacturing License

Shanghai, July 1st, 2022 – BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International
July 01, 2022

BioDuro-Sundia Appoints Kent Payne CEO

BioDuro-Sundia names Kent Payne, PhD, as CEO, aiming for expanded growth and innovation in drug discovery, development, and commercial services globally
February 14, 2022
Total 85 12345678...1617
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all